Guidance for Industry: Clinical Pharmacogenomics. Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling.

摘要

This guidance is intended to assist the pharmaceutical industry and other investigators engaged in new drug development in evaluating how variations in the human genome, specifically DNA sequence variants, could affect a drugs pharmacokinetics (PK), pharmacodynamics (PD), efficacy, or safety.2 The guidance provides recommendations on when and how genomic information should be considered to address questions arising during drug development and regulatory review.